We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Arcellx, Inc. (ACLX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcellx, Inc. is a member of our Medical group, which includes 1091 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arcellx, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACLX's full-year earnings has moved 2.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ACLX has returned 11% so far this year. At the same time, Medical stocks have lost an average of 10.9%. As we can see, Arcellx, Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Ardelyx (ARDX - Free Report) . The stock is up 38.3% year-to-date.
In Ardelyx's case, the consensus EPS estimate for the current year increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcellx, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 529 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 22.5% this year, meaning that ACLX is performing better in terms of year-to-date returns.
In contrast, Ardelyx falls under the Medical - Drugs industry. Currently, this industry has 193 stocks and is ranked #92. Since the beginning of the year, the industry has moved -18.7%.
Investors interested in the Medical sector may want to keep a close eye on Arcellx, Inc. and Ardelyx as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Arcellx, Inc. (ACLX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcellx, Inc. is a member of our Medical group, which includes 1091 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arcellx, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACLX's full-year earnings has moved 2.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ACLX has returned 11% so far this year. At the same time, Medical stocks have lost an average of 10.9%. As we can see, Arcellx, Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Ardelyx (ARDX - Free Report) . The stock is up 38.3% year-to-date.
In Ardelyx's case, the consensus EPS estimate for the current year increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcellx, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 529 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 22.5% this year, meaning that ACLX is performing better in terms of year-to-date returns.
In contrast, Ardelyx falls under the Medical - Drugs industry. Currently, this industry has 193 stocks and is ranked #92. Since the beginning of the year, the industry has moved -18.7%.
Investors interested in the Medical sector may want to keep a close eye on Arcellx, Inc. and Ardelyx as they attempt to continue their solid performance.